Marshall Wace, LLP Ultragenyx Pharmaceutical Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 822,012 shares of RARE stock, worth $36.9 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

822,012

Previous 1,133,100 27.45%

Holding current value

$36.9 Million

Previous $46.6 Million 1.95%

% of portfolio

0.06%

Previous 0.06%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $12.5 Million - $18.5 Million	-311,088 Reduced 27.45%	822,012 $45.7 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $6.14 Million - $8.47 Million	164,110 Added 16.94%	1,133,100 $46.6 Million
Q1 2024 May 15, 2024	SELL	$43.02 - $53.69 $22.4 Million - $27.9 Million	-520,496 Reduced 34.94%	968,990 $45.2 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $17.4 Million - $27 Million	548,723 Added 58.33%	1,489,486 $71.2 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $493,279 - $659,119	14,126 Added 1.52%	940,763 $33.5 Million
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $788,533 - $1.1 Million	21,112 Added 2.33%	926,637 $42.7 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $21.1 Million - $27.8 Million	570,100 Added 169.96%	905,525 $36.3 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $8.59 Million - $11.8 Million	254,711 Added 315.57%	335,425 $15.5 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $10.8 Million - $17.9 Million	-270,936 Reduced 77.05%	80,714 $3.34 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $1.55 Million - $2.89 Million	-33,803 Reduced 8.77%	351,650 $21 Million
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $9.41 Million - $12.8 Million	151,223 Added 64.56%	385,453 $28 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $15.1 Million - $17.9 Million	204,288 Added 682.28%	234,230 $19.7 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $435,339 - $572,108	-5,587 Reduced 15.73%	29,942 $2.7 Million
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $3.28 Million - $4.11 Million	35,529 New	35,529 $3.39 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $2.78 Million - $4.36 Million	-26,014 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $2.2 Million - $4.61 Million	26,014 New	26,014 $3.6 Million

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.15B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Ultragenyx Pharmaceutical Inc. Transaction History